A gene editing company used Urchin to identify therapeutic whitespace beyond conventional expert search.

Context

A gene editing company was exploring how to deploy a novel therapeutic modality across a broad disease landscape.

The team had already spent years thinking deeply about the opportunity space and had developed a strong intuition for where the field was likely to go. The question was not whether promising opportunities existed; it was whether there were still valuable opportunities hiding outside the boundaries of conventional expert search.

The Challenge

Emerging therapeutic modalities tend to converge rapidly on the same handful of diseases, targets, and development strategies. Teams draw from the same literature, the same conferences, and the same set of visible success stories, creating a strong pull toward consensus programs.

Finding truly differentiated opportunities requires searching beyond familiar biological pathways while simultaneously respecting the practical realities of drug development, delivery, patient populations, and competitive dynamics.

The challenge was not simply to search the existing landscape, but to creatively expand the search space itself before systematically exploring it for high-value opportunities that sit outside conventional patterns of thinking.

What Urchin Did

Urchin conducted a breadth-first exploration of the therapeutic opportunity landscape, combining biological reasoning with translational and commercial considerations.

The engagement:

• Evaluated 200+ candidate opportunities across disease biology, human genetics, competitive landscape, delivery feasibility, clinical tractability, and strategic differentiation.
• Iteratively refined the search over 3 rounds based on feedback from the scientific team.
• Developed 11 opportunities into full analyses, elevating 6 to a primary shortlist spanning multiple therapeutic categories and development strategies, including several that challenged existing assumptions about where durable value might emerge.
• Generated structured reasoning traces and deep-dive analyses for shortlisted opportunities to support downstream prioritization and decision-making.

As the engagement progressed, the search process itself became informative. New opportunities increasingly clustered around previously identified biological themes, suggesting that the landscape had become substantially mapped under the team's current assumptions.

Impact

Several of the highest-priority opportunities surfaced by Urchin were described by the project's scientific lead as candidates that he would not have identified independently, despite having spent years thinking about this therapeutic space. One example was a therapeutic strategy whose value came specifically from being permanent: a mechanism where irreversibility was not a liability but the primary advantage, and where no conventional pharmacologic approach could fully replicate the desired effect.

The engagement validated that systematic search can complement expert intuition by exploring parts of the biological search space that human reasoning alone is unlikely to visit consistently. The combination of creative reframing and systematic exploration helped reveal entirely new categories of opportunity rather than simply reprioritizing familiar ideas.

Reaching convergence at the end of the search process gave the team confidence that their understanding of the opportunity landscape was approaching completeness. It also clarified where durable value in the modality was likely to emerge as the field matured. This made it possible to distinguish opportunities that were merely interesting from opportunities that represented genuine strategic whitespace.